J. Wanders

23.6k citations

133 papers · 19.7k · 2 hit papers · h-index 39

Impact in

Oncology top 0.1%
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 79
- Cancer Treatment and Pharmacology 54
- Colorectal Cancer Treatments and Studies 23
- HER2/EGFR in Cancer Research 15
- Neutropenia and Cancer Infections 7
Molecular Biology 40
- Cancer therapeutics and mechanisms 26

Co-authors: Jaap Verweij (27 shared papers)Elizabeth A. Eisenhauer (3 shared papers)M. van Glabbeke (4 shared papers)Larry Rubinstein (2 shared papers)Richard Kaplan (2 shared papers)Michaele C. Christian (2 shared papers)Patrick Therasse (2 shared papers)Allan T. van Oosterom (2 shared papers)
Journals: European Journal of Cancer (30 papers)Journal of Clinical Oncology (21 papers)Annals of Oncology (16 papers)British Journal of Cancer (11 papers)Investigational New Drugs (8 papers)
Partner nations: Netherlands United Kingdom Belgium

In The Last Decade

J. Wanders

132 papers receiving 19.2k citations

J. Wanders's Hit Papers

align trajectories log scale

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study 2011 · 817 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2011 The Lancet
2000 JNCI Journal of the National Cancer Institute

Peers

Countries citing papers authored by J. Wanders

Since Specialization

Citations

This map shows the geographic impact of J. Wanders's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Wanders with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Wanders more than expected).

Fields of papers citing papers by J. Wanders

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Wanders. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Wanders. The network helps show where J. Wanders may publish in the future.

Co-authors

The 25 scholars most cited alongside J. Wanders, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Wanders Line = papers co-authored together J. Wanders links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 133 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	New Guidelines to Evaluate the Response to Treatment in Solid Tumors JNCI Journal of the National Cancer Institute ·Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, J. Wanders, Richard Kaplan, Larry Rubinstein, Jaap Verweij, M. van Glabbeke, Allan T. van Oosterom, Michaele C. Christian, Steve G. Gwyther Hit paper breakdown →	2000	13609
2	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study The Lancet ·Javier Cortés, Joyce O’Shaughnessy, David Loesch, Joanne L. Blum, Linda T. Vahdat, Katarína Petráková, P. Chollet, Alexey Manikas, Véronique Dièras, T. Delozier, Vladimir Vladimirov, Fátima Cardoso, Han Koh, Philippe Bougnoux, Corina E. Dutcus, Seth Seegobin, Denis Mir, Nicole Meneses, J. Wanders, Chris Twelves Hit paper breakdown →	2011	817
3	New guidelines to evaluate the response to treatment in solid tumors Breast Cancer ·Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer, J. Wanders, Richard Kaplan, Larry Rubinstein, Jaap Verweij, M. van Glabbeke, Allan T. van Oosterom, Michaele C. Christian, Steve G. Gwyther	2005	476
4	Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. Journal of Clinical Oncology ·Andrea Ardizzoni, H. Hansen, P Dombernowsky, Teresa Gamucci, Steven Kaplan, P Postmus, Giuseppe Giaccone, Benedikt Schaefer, J. Wanders, Jaap Verweij	1997	377
5	Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin European Journal of Cancer ·M. Borner, Patrick Schöffski, Ronald de Wit, Francesco Caponigro, G. Comella, Aarón Sulkes, G. Greim, Godefridus J. Peters, Kasper van der Born, J. Wanders, R.F de Boer, Christophe Martin, P. Fumoleau	2002	276
6	Docetaxel (TaxotereTM) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group British Journal of Cancer ·Aarón Sulkes, Joan A. Smyth, C. Sessa, LY Dirix, J. B. Vermorken, Stuart Kaye, J. Wanders, H. Franklin, N LeBail, Jaap Verweij	1994	198
7	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes The Lancet Oncology ·Patrick Schöffski, Isabelle Laure Ray-Coquard, Angela Cioffi, Nguyen Bin Bui, Sebastian Bauer, J. T. Hartmann, Anders Krarup‐Hansen, Viktor Grünwald, Raf Sciot, Herlinde Dumez, Jean‐Yves Blay, Axel Le Cesne, J. Wanders, Carolyn Hayward, Sandrine Marréaud, M. Ouali, Peter Hohenberger	2011	175
8	Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. PubMed ·Andreas M. Kaufmann, Peter L. Stern, Elaine M. Rankin, Harald Sommer, V. Nuessler, Achim Schneider, Malcom Adams, Toli S. Onon, Thomas Bauknecht, Uwe Wagner, Karlijn Kroon, Julian Hickling, Christopher M. Boswell, Simon Stacey, Henry C Kitchener, Jennifer Gillard, J. Wanders, J St Clair Roberts, H. Zwierzina	2002	171
9	Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine Journal of Clinical Oncology ·Javier Cortés, Linda T. Vahdat, Joanne L. Blum, Chris Twelves, Mario Campone, Henri Roché, Thomas Bachelot, Ahmad Awada, Robert Paridaens, Anthony Gonçalvès, Dale E. Shuster, J. Wanders, Fang Fang, Renuka Gurnani, Elaine Richmond, Patricia E. Cole, Simon Ashworth, Mary Ann Allison	2010	164
10	A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours British Journal of Cancer ·David S. Boss, Hilary Glen, Jos H. Beijnen, M Keesen, R.S. Morrison, B. Tait, William Copalu, Antonina Joanna Mazur, J. Wanders, James P. O’Brien, Jan H.M. Schellens, T.R. Jeffry Evans	2012	153
11	Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG) British Journal of Cancer ·Thomas Cerny, Steven Kaplan, N. Pavlidis, Patrick Schöffski, Ron Epelbaum, J Van Meerbeek, J. Wanders, H. R. Franklin, S.B. Kaye	1994	145
12	Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report European Journal of Cancer ·M. Marchand, Cornelis J.A. Punt, Steinar Aamdal, Bernard Escudier, Wim H.J. Kruit, Ulrich Keilholz, Leif Håkansson, Nicolas van Baren, Yves Humblet, Peter F.A. Mulders, Marie‐Françoise Avril, Alexander Eggermont, Carmen Scheibenbogen, John Uiters, J. Wanders, M Delire, Thierry Boon, G. Stoter	2002	135
13	Coping with toxicities of docetaxel (TaxotereTM) Annals of Oncology ·D. Schrijvers, J. Wanders, Luc Dirix, A. Prové, I. Vonck, A. van Oosterom, S.B. Kaye	1993	123
14	A phase II trial with Docetaxel (Taxotere™) in second line treatment with chemotherapy for advanced breast cancer Annals of Oncology ·W.W. ten Bokkel Huinink, A. Prové, Martine Piccart, William P. Steward, Thomas Tursz, J. Wanders, H. Franklin, M. Clavel, Jaap Verweij, May Alakl, M. Bayssas, Stan B. Kaye	1994	117
15	A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck Annals of Oncology ·G. Catimel, Jan B. Vermorken, M. Clavel, PHM de Mulder, Ian Judson, C. Sessa, Martine Piccart, U. Bruntsch, Jaap Verweij, J. Wanders, (unknown), (unknown), (unknown), (unknown), (unknown)	1994	108
16	Activity of docetaxel (Taxotere) in small cell lung cancer European Journal of Cancer ·J F Smyth, I E Smith, C. Sessa, Patrick Schöffski, J. Wanders, H. Franklin, Stuart Kaye	1994	106
17	Docetaxel: an Active New Drug for Treatment of Advanced Epithelial Ovarian Cancer JNCI Journal of the National Cancer Institute ·Martine Piccart, Martin Gore, W. ten Bokkel Huinink, A. van Oosterom, Jaco J. Verweij, J. Wanders, H. Frankli, M. Bayssas, S.B. Kaye	1995	101
18	Phase II trial with S-1 in chemotherapy-naıve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG) European Journal of Cancer ·P. Chollet, Patrick Schöffski, K. Weigang-Köhler, Jan H.M. Schellens, H. Curé, Nicholas Pavlidis, Victor Grünwald, R. de Boer, J. Wanders, P. Fumoleau	2003	88
19	Docetaxel and cisplatin: An active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck Annals of Oncology ·Patrick Schöffski, G. Catimel, A.S.T. Planting, Droz Jp, Jaap Verweij, D. Schrijvers, L. Gras, A. H. G. J. Schrijvers, J. Wanders, A.-R. Hanauske	1999	83
20	Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer Clinical Breast Cancer ·Chris Twelves, Javier Cortés, Linda T. Vahdat, J. Wanders, (unknown), Peter A. Kaufman	2010	83

About J. Wanders

J. Wanders is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Cancer Research and Organic Chemistry, having authored 133 papers that have together received 19.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (54 papers), Cancer therapeutics and mechanisms (26 papers), Colorectal Cancer Treatments and Studies (23 papers), HER2/EGFR in Cancer Research (15 papers), Advanced Breast Cancer Therapies (11 papers), Lung Cancer Treatments and Mutations (11 papers), Breast Cancer Treatment Studies (9 papers) and Neutropenia and Cancer Infections (7 papers). The work is most often cited by research in Oncology (6.8k citations), Hepatology (1.4k citations), Pulmonary and Respiratory Medicine (4.9k citations), Otorhinolaryngology (429 citations) and Cancer Research (1.5k citations). J. Wanders has collaborated with scholars based in Netherlands, United Kingdom and Belgium. Frequent co-authors include Jaap Verweij, Elizabeth A. Eisenhauer, M. van Glabbeke, Larry Rubinstein, Richard Kaplan, Michaele C. Christian, Patrick Therasse, Allan T. van Oosterom, Susan G. Arbuck and Patrick Schöffski. Their work appears in journals such as European Journal of Cancer, Journal of Clinical Oncology, Annals of Oncology, British Journal of Cancer and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

J. Wanders

Impact in

Papers in i

In The Last Decade

J. Wanders

J. Wanders's Hit Papers

Peers

Countries citing papers authored by J. Wanders

Fields of papers citing papers by J. Wanders

All Works

About J. Wanders

Explore authors with similar magnitude of impact

Papers in